Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc.

SLNONYSE / NASDAQHealthcareSmall cap

$53.01$0.00 (0.0%)

Last close · Data as of May 18, 2026

Market cap
$2.8B
P/E
132.3x
EV / EBITDA
96.7x
Revenue
$190.4M
Net margin
11.0%
ROCE
3.0%

Hidden because the last close is more than three trading days older than the latest prices of its class.

Soleno Therapeutics, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 18 May 2026 close.

1M
Stale
3M
Stale
6M
Stale
1Y
Stale
5Y
Stale
  • Hidden because the last close is more than three trading days older than the latest prices of its class.

52-week range

Day change $0.00 (0.0%) from $53 to $53 · Last close May 18, 2026

Best weekday to invest, historically

The same weekly amount in SLNO, bought on each weekday since 2021.

News & filings

What Soleno Therapeutics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthReturn on equity rose from -71.7% to 4.6% between fiscal 2024 and fiscal 2025.

Concerns

No concern stands out for this company on the data on file.

  • Prices are as of 18 May 2026; price-based points are paused until newer prices arrive.

Prices to the 18 May 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.

Sector
Healthcare
Shares outstanding
52.2M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$2.8B
P/E
132.3x
P/B
6.1x
EV / EBITDA
96.7x
EV / Sales
14.4x
P/S
14.5x
52-week high
$88.49
52-week low
$30.05

Profitability

Operating margin
7.9%
Net margin
11.0%
EBITDA margin
14.9%
ROE
4.6%
ROCE
3.0%
ROIC
4.8%
ROA
3.7%
Asset turnover
0.34

Growth

Revenue
$190.4M
Net profit growth, 1Y
-111.9%
Free cash flow
$46.7M

Solvency

Current ratio
5.80
Debt / Equity
0.12
Debt / Assets
0.09
CFO / Net profit
2.24
Cash / Market cap
2.5%

Where the revenue went

Of every $100 of FY2025 revenue, $11 was left as net income.

Soleno Therapeutics, Inc. income statement flow, FY2025
Soleno Therapeutics, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$2.7M
RevenueGross profit$187.7M
Gross profitOperating expenses$172.8M
Gross profitOperating income$14.9M
Operating incomePretax income$14.9M
Interest and other incomePretax income$5.9M
Pretax incomeNet income$20.9M

Revenue and net profit

Annual revenue, with net profit as the dashed line.

Soleno Therapeutics, Inc. revenue and net profit by fiscal year
Soleno Therapeutics, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$0.00-$24.1M
FY2023$0.00-$39.0M
FY2024$0.00-$175.8M
FY2025$190.4M$20.9M

Cash flows

FY2025: $46.8M from operations, $46.7M free after investment (dashed).

Soleno Therapeutics, Inc. operating and free cash flow by fiscal year
Soleno Therapeutics, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$20.8M-$20.8M
FY2023-$24.9M-$24.9M
FY2024-$69.1M-$69.3M
FY2025$46.8M$46.7M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$190.4M
EBITDA
$28.4M
Net profit
$20.9M
Cash from operations
$46.8M
Free cash flow
$46.7M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$190.4M$28.4M$20.9M$46.7M4.6%—-111.9%

Monthly returns

Month-by-month returns of SLNO across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$563.8M
Liabilities$113.7M
Equity$450.1M
Paid-in capital$881.0M
Retained earnings-$431.4M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; SLNO highlighted.

P/E against peers

SLNO trades at 132.3x earnings against a peer median of -10.8x.

  1. Soleno Therapeutics, Inc. (this company)132.3x

Not shown (no positive earnings and no EV / Sales): Disc Medicine, Inc., Definium Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Soleno Therapeutics, Inc.SLNOthis company$2.8B132.3x6.1x4.6%96.7x
LifeStance Health Group, Inc.LFST$2.9B301.9x1.9x0.6%39.9x
Adaptive Biotechnologies CorporationADPT$2.9B—13.2x-27.2%—
GRAIL, Inc.GRAL$2.9B-7.0x1.1x-15.8%-7.0x
Brookdale Senior Living Inc.BKD$2.8B-10.8x-63.4x587.0%23.5x
Arcutis Biotherapeutics, Inc.ARQT$2.7B-170.1x14.5x-8.5%1582.5x
Disc Medicine, Inc.IRON$2.7B-12.8x3.7x-28.7%-12.8x
Definium Therapeutics, Inc.DFTX$2.7B-14.6x8.1x-55.3%-13.8x
Alumis Inc.ALMS$2.6B-10.7x8.6x-80.8%-5.7x
Peer median—-10.8x5.9x-21.5%-5.7x

Year-to-date ROI

SLNO since 1 January, against earlier years.

Historical volatility

SLNO's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Soleno Therapeutics, Inc. operating margin by fiscal year
Soleno Therapeutics, Inc. operating margin by fiscal year
DateOperating margin
FY20257.9%
LineFY2025
Cost of revenueCost Of Revenue$2.7M
Gross profitGross Profit$187.7M
Operating expensesOperating Expense$172.8M
Research and developmentResearch And Development$40.6M
Total expensesTotal Expenses$175.5M
Pretax incomePretax Income$20.9M

Learn while you research

Academy chapters picked for Soleno Therapeutics, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 132.3, learn when high multiples are justified.6 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →